CWBR CohBar is a clinical stage biotechnology company which develops mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases.
CWBR closed few months ago a $15.0 Million Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now.
Cantor Fitzgerald brokerage has a $2.5 price target for it.
CWBR closed few months ago a $15.0 Million Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now.
Cantor Fitzgerald brokerage has a $2.5 price target for it.
Transaction en cours:
CWBR Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals www.patreon.com/PremiumOptionsSignals
RESULTS www.bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals www.patreon.com/PremiumOptionsSignals
RESULTS www.bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880